Test Price
2,800 AED✅ Home Collection Available
CFH Gene Hemolytic Uremic Syndrome Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This advanced genetic test employs Next-Generation Sequencing (NGS) to detect mutations in the CFH gene associated with atypical hemolytic uremic syndrome (aHUS). Our laboratory is ISO 9001:2015 accredited and licensed by the Dubai Health Authority, ensuring diagnostic sensitivity of 99.9%. Each test includes a comprehensive genetic counselling session. Temperature-controlled home collection and VIP mobile phlebotomy are available daily. Post-test clinical guidance is provided by our specialist medical genetics team. We strictly adhere to UAE data privacy regulations.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This NGS-based test sequences the entire CFH gene (all exons, splice sites, and deep intronic regions) to detect point mutations, small indels, and copy number variants associated with atypical hemolytic uremic syndrome (aHUS). High-quality genetic profiling confirms diagnosis, guides treatment planning, and enables family risk assessment.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Technology | NGS – all coding regions & CNV detection | Sanger – limited to single exons; no CNV detection |
| Turnaround Time | 3–4 weeks | 2–3 weeks per exon (multiple runs required) |
| Diagnostic Yield | >95% for CFH-related aHUS | ~70% (misses large deletions/duplications) |
| Cost | 2800 AED – comprehensive panel | Higher cumulative cost if multiple segments needed |
Physician Insight & Safety Protocols
"As a consultant in medical genetics, I emphasize that this CFH NGS test must be interpreted within the full clinical context. A positive result confirms predisposition to aHUS and facilitates family screening and prophylactic strategies. A negative result does not exclude other complement-mediated disorders. Genetic counselling and nephrology consultation are integral to the process."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication Precautions
⚠️ Medication Advisory:
Do not discontinue prescribed medication without consulting your doctor. If you are on eculizumab or other complement inhibitors, your test appointment may require special coordination with the nephrology team.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active thrombotic microangiopathy crisis requiring emergency plasmapheresis; pregnant patients in third trimester (risk of sample instability).
- Exclusion: Lack of informed consent signed by legal guardian for minors (in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Red Flag: If you experience sudden fever, bruising, or confusion, seek immediate emergency care – do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the CFH gene HUS NGS test, and why is it ordered?
Answer: This advanced genetic test analyzes the entire CFH gene using next-generation sequencing to identify mutations that cause atypical hemolytic uremic syndrome. It guides diagnosis, treatment, and family risk assessment. The comprehensive analysis helps confirm aHUS and informs prophylactic strategies for at-risk relatives.
2. How is the sample collected, and does it require fasting?
Answer: A simple blood draw or buccal swab is collected by a trained phlebotomist during a home visit. No fasting or medication cessation is required unless your doctor advises otherwise. Please inform the medical team of all current medications.
3. How should I prepare for the genetic counselling session and test?
Answer: Prepare a detailed family medical history, list of medications, and any previous lab reports. You will receive genetic counselling to draw a pedigree chart and understand the implications of results. Clinical history and family pedigree are mandatory components of this test.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Security: This test is processed under the strict provisions of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, anonymized, and stored within secure UAE-based servers. Patient consent and clinical safety are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our Dubai Health Authority license (No. 1143) ensures full compliance with local healthcare regulations.
Clinical & Logistical Metadata
| Test Name | CFH Gene Hemolytic Uremic Syndrome NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or buccal swab |
| Methodology Used | Next-Generation Sequencing (NGS) – whole gene analysis including CNV detection |
| ICD-10-CM Code | D59.3 (Hemolytic-uremic syndrome) |
| LOINC Code | 21661-6 (CFH gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians